Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioadaptives (BDPT) Equity Ratio (2019 - 2025)

Bioadaptives' Equity Ratio history spans 7 years, with the latest figure at 11.78 for Q3 2025.

  • For Q3 2025, Equity Ratio rose 69.72% year-over-year to 11.78; the TTM value through Sep 2025 reached 11.78, up 69.72%, while the annual FY2024 figure was 5.59, 64.7% up from the prior year.
  • Equity Ratio for Q3 2025 was 11.78 at Bioadaptives, down from 4.52 in the prior quarter.
  • Across five years, Equity Ratio topped out at 3.48 in Q3 2023 and bottomed at 213.82 in Q2 2024.
  • The 5-year median for Equity Ratio is 15.83 (2023), against an average of 34.82.
  • The largest annual shift saw Equity Ratio tumbled 1018.35% in 2024 before it skyrocketed 97.89% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 7.36 in 2021, then plummeted by 428.79% to 38.9 in 2022, then surged by 59.3% to 15.83 in 2023, then surged by 64.7% to 5.59 in 2024, then tumbled by 110.77% to 11.78 in 2025.
  • Per Business Quant, the three most recent readings for BDPT's Equity Ratio are 11.78 (Q3 2025), 4.52 (Q2 2025), and 14.22 (Q1 2025).